---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Ponatinib Hydrochloride - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ponatinibhydrochloride
version: v1
---

# Ponatinib Hydrochloride - NCI

# Ponatinib Hydrochloride

Placeholder slot

(poh-NA-tih-nib HY-droh-KLOR-ide)

This page contains brief information about ponatinib hydrochloride
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Iclusig

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=PONATINIB+HYDROCHLORIDE&pagesize=20&page=1&audience=consumer)

## Use in Cancer

Ponatinib hydrochloride
is approved
for use in adults to treat:

- **[Acute lymphoblastic leukemia](/Common/PopUps/popDefinition.aspx?id=45586&version=Patient&language=English)** that is [Philadelphia chromosome](/Common/PopUps/popDefinition.aspx?id=44179&version=Patient&language=English) [positive](/Common/PopUps/popDefinition.aspx?id=44710&version=Patient&language=English). It is used:
- With chemotherapy in patients whose cancer is newly diagnosed.¹
- Alone in patients whose cancer has a [T315I mutation](/Common/PopUps/popDefinition.aspx?id=806984&version=Patient&language=English) or cannot be treated with other [kinase inhibitors](/Common/PopUps/popDefinition.aspx?id=750798&version=Patient&language=English).
- **[Chronic myelogenous leukemia](/Common/PopUps/popDefinition.aspx?id=44901&version=Patient&language=English)** (CML). It is used:
- In patients with [chronic phase CML](/Common/PopUps/popDefinition.aspx?id=45160&version=Patient&language=English) whose cancer did not respond to at least two kinase inhibitors or who cannot be treated with other kinase inhibitors.
- In patients with [accelerated phase](/Common/PopUps/popDefinition.aspx?id=46212&version=Patient&language=English) or [blastic phase CML](/Common/PopUps/popDefinition.aspx?id=46113&version=Patient&language=English) whose cancer cannot be treated with other kinase inhibitors.
- In patients whose cancer has a T315I mutation.

Ponatinib hydrochloride is not approved to treat newly diagnosed chronic phase CML.

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that ponatinib hydrochloride provides a clinical benefit in these patients.

Ponatinib hydrochloride is being studied in the treatment of other types of cancer.

## More About Ponatinib Hydrochloride

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/595060) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Ponatinib Hydrochloride](https://medlineplus.gov/druginfo/meds/a613029.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Ponatinib Hydrochloride](https://www.cancer.gov/research/participate/clinical-trials/intervention/C78194) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
